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ABSTRACT
We analyzed outcomes of patients with myelodysplastic syndrome (MDS) or secondary acute myelogenous
leukemia (sAML) that were treated at our institution with a reduced intensity conditioning (RIC) regimen of
550-cGy total body irradiation and cyclophosphamide followed by related donor (RD) or unrelated donor
(URD) transplantation. Fifty-one consecutive patients with MDS or sAML received this RIC regimen and
URD (n 30) or RD (n 21) stem cells. Graft-versus-host disease prophylaxis consisted of cyclosporine alone
(RD) or with corticosteroids and methotrexate (URD). Median patient age was 44 years. With a median
follow-up of 3.7 years after transplantation in the 19 surviving patients (37%), Kaplan-Meier estimates of
overall survival were 88%, 46%, 33%, and 11% for patients transplanted with sAML in remission, refractory
anemia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or sAML
refractory/untreated, respectively. Kaplan-Meier estimates of relapse-free survival were 75%, 46%, 33%, and
11%, respectively. Overall, the cumulative incidences of relapse and transplant-related mortality were 27% and
37%, respectively. In patients with MDS, this is an effective RIC regimen for allogeneic transplantation that
can be used as an alternative to other RIC or conventional conditioning regimens.
© 2006 American Society for Blood and Marrow Transplantation
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Myelodysplastic syndromes (MDSs) are clonal bone
arrow disorders manifested by progressive cytopenias
nd an increased risk of acute myelogenous leukemia
AML). Median survival for patients with newly diag-
osed MDS that is managed with standard (nontrans-
lant) care ranges from 5.7 to .4 years, depending on risk hharacteristics deﬁned in the International Prognostic
coring System (IPSS) [1]. Allogeneic stem cell trans-
lantation remains the only potentially curative therapy
2-4]. However, most patients with MDS are 50 years
f age and have comorbidities, making them poor can-
idates for allogeneic transplantation according to con-
entional myeloablative conditioning regimens due to a
igh risk of regimen-related organ toxicity (RROT) and
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C. L. Hallemeier et al.750reatment-related mortality (TRM) [3-7]. Recent efforts
ave focused on developing nonmyeloablative and re-
uced intensity conditioning (RIC) regimens in an effort
o decrease toxicity and improve survival in patients with
DS undergoing allogeneic transplant.
Since 1995, we have investigated a RIC regimen of
50-cGy single-exposure total body irradiation (TBI)
iven with cyclophosphamide for allogeneic trans-
lantation for patients with hematologic malignancies.
n the related donor (RD) setting, this RIC regimen
esulted in durable and complete donor cell engraft-
ent, no graft failure, and low rates of serious RROT
nd TRM [8]. In patients with chronic myelogenous
eukemia in chronic phase and acute leukemia in ﬁrst
omplete remission (CR) who received this RIC reg-
men for allogeneic transplantation, the overall sur-
ival at 2 years was 80% [8,9]. In the unrelated
onor (URD) transplantation setting, this regimen
esulted in relatively low rates of RROT, TRM, and
raft failure [10,11]. Based on this favorable experi-
nce, we retrospectively reviewed the outcomes of all
atients with MDS and secondary AML (sAML) who
nderwent allogeneic transplantation and were treated
ith this RIC regimen at our institution.
ETHODS
atients
Patients in this analysis constituted a subset of
hose treated in 2 contemporaneous institutional
hase II protocols that examined the safety and efﬁ-
acy of TBI delivered in a single dose (550 cGy) and at
high dose rate (30 cGy/min) and cyclophosphamide
60 mg · kg1 · d1 for 2 days) as a RIC regimen for
D and URD allogeneic transplantation in patients
ith hematologic malignancies [8,10].
Included in this analysis are the 51 consecutive
dult patients (18 years of age) with an initial diag-
osis of MDS as deﬁned by French-American-British
FAB) criteria [12]. Patients with chronic monomyelo-
ytic leukemia, myeloproliferative disorders, and pri-
ary myeloﬁbrosis were excluded. Patients with treat-
ent-related MDS (t-MDS) were included only if in
emission from the primary disease. Patients with
reatment-related AML without a clinically docu-
ented preceding MDS phase were also excluded.
tudy-speciﬁc exclusion criteria for both protocols
ncluded Eastern Cooperative Oncology Group per-
ormance status 2, left ventricular ejection fraction
40%, diffusion lung capacity of carbon monoxide
orrected for hemoglobin 40% of predicted, serum
reatinine level 2.0 mg/dL, liver enzymes 5 times
ormal, active infection, HIV positivity, or positive
regnancy test results. In patients fulﬁlling the inclu-
ion and exclusion criteria, stem cell transplantation
as recommended in those with morphologically ad- wanced disease or those with refractory anemia with
igh-risk characteristics for disease progression (ad-
erse cytogenetics and/or t-MDS) or life-threatening
ytopenias. The institutional review board of Wash-
ngton University School of Medicine approved both
rotocols and each patient gave written informed con-
ent. Patients were accrued between November 1995
nd July 2002 and follow-up was performed through
uly 2004. During this interval, 1 other patient meeting
hese study criteria underwent allogeneic transplantation
t our institution; this patient received busulfan and
yclophosphamide conditioning (not eligible to receive
BI) and was not included in this analysis.
tem Cells
Patients undergoing RD transplantation received
eripheral blood stem cells (PBSCs) from an HLA-
dentical sibling (6/6 match at A, B, and DRB1 loci)
obilized with granulocyte colony-stimulating factor
G-CSF) alone, granulocyte-macrophage colony-stimu-
ating factor alone, or G-CSF plus granulocyte-mac-
ophage colony-stimulating factor. Administration of
rowth factors for mobilization and stem cell collection
y leukapheresis were performed as previously described
8,13]. In patients undergoing URD transplantation, do-
or selection and bone marrow (BM) collection were
acilitated by the National Marrow Donor Program.
rimary criteria for URD donor selection included HLA
ompatibility, deﬁned as a 6-of-6 antigen match (at A, B,
nd DRB1 loci) or a 5-of-6 antigen match (single-anti-
en mismatch at A, B, or DRB1 locus), with a preference
or the former. HLA class 1 antigens were serologically
yped before December 2000 and typed with low-reso-
ution DNA methods thereafter [10]. High-resolution
RB1 typing was performed by polymerase chain reac-
ion methods [10]. PBSC and BM were not T-cell de-
leted. BM was depleted of plasma and red blood cells if
he donor and recipient were ABO incompatible. Stem
ells were infused fresh into the recipient on day 0.
onditioning Regimen
The regimen included cyclophosphamide (60
g · kg1 · d1) given on days 3 and 2, followed
y TBI (550 cGy) administered in a single dose on day
1. The median dose rate delivered was 33.2 cGy/
in (range, 25.3-37.2). TBI was delivered in parallel
pposed lateral ﬁelds with 6-MeV photons using a
linac 600 CD (Varian Medical Systems, Alpharetta,
a), as previously described [8].
raft-versus-Host Disease Prophylaxis
All patients received cyclosporine beginning on
ay 2 and continuing through day 100, with dose
djustments made to achieve a drug concentration of
00 to 400 ng/mL. Around day 100, cyclosporine
as tapered at a rate of 5% per week in patients with
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Intermediate-Dose TBI-Based RIC and Allogeneic BMT for MDS 751o active graft-versus-host disease (GVHD). Patients
ndergoing URD transplantation also received intra-
enous methotrexate and methylprednisolone. Meth-
trexate was administered intravenously on day 1
10 mg/m2) and on days 3 and 6 (7.5 mg/m2).
ethylprednisolone (1 mg · kg1 · d1) was given
rom days 7 to 28 and then tapered over 6 weeks.
welve patients (4 RD and 8 URD) also received
eritransplantation hydroxychloroquine (800 mg/day)
rom day 21 through day 100 [14].
Acute and chronic GVHDs were graded using
tandard methods [8,15-17]. Diagnosis and treatment
f GVHD have been previously deﬁned [8].
upportive Care
All patients received transfusion support, prophy-
actic acyclovir, empiric antimicrobial therapy, and
ytomegalovirus surveillance monitoring and treat-
ent as previously deﬁned [8,10]. G-CSF (10
g · kg1 · d1 subcutaneously) was started on day
1 in patients undergoing RD transplantation and on
ay 7 in patients undergoing URD transplantation.
n all patients, G-CSF was continued until the absolute
eutrophil count was 1500/L for 2 consecutive days.
atients undergoing URD transplantation also received
rophylactic itraconazole, ciproﬂoxacin, and rifampin.
valuation, Endpoints, and Statistics
Disease status pre-transplant was deﬁned at diag-
osis and immediately before conditioning. Status was
eﬁned as refractory anemia (RA), RA with ringed
ideroblasts, RA with excess blasts (RAEB), RA with
xcess blasts in transformation (RAEB-t), or sAML, as
etermined by the FAB criteria [12]. Secondary AML
as deﬁned as an initial diagnosis of MDS with sub-
equent transformation to AML. Of the 17 patients
ith sAML, 15 received pretransplantation induction
hemotherapy and 2 did not. Patients with sAML who
eceived pretransplantation chemotherapy were con-
idered to be in remission at transplantation if they
emonstrated 5% blasts by morphology in the BM,
bsence of blasts in the peripheral blood, and absence
f chromosomal abnormalities in the marrow (if pre-
iously present). In addition, complete blood cell
ount must have demonstrated an absolute neutrophil
ount 1000/L, platelet count 100 000/L, and
emoglobin level 10 g/dL. The IPSS was also used
n assessing disease status in patients with MDS [1].
Post-transplantation evaluations of chimerism,
ROT, GVHD, TRM, disease status, and survival
tatus were performed on days30,100,180, year
, and yearly thereafter. Chimerism of whole BM cells
as assessed by using variable number tandem repeat
robes, with a sensitivity of 1% to 5%, as previously
eﬁned [8,18,19]. Patients with relapsed disease were
ot evaluable for chimerism or graft failure at the time af or subsequent to relapse. RROT was graded using
riteria of the National Cancer Institute (NCI) for
M transplantation studies [20]. Patients who died
efore neutrophil engraftment were not evaluable for
cute GVHD; patients who died or relapsed before
ay 100 were not evaluable for chronic GVHD.
elapsed disease was deﬁned as morphologic evidence
f MDS at any time after transplantation and/or cy-
ogenetic reappearance of the initial clone for 1
valuation after transplantation.
Analysis of data was performed with StatView 4.5
Abacus Concepts Inc, Berkeley, Calif). Relapse-free
urvival (RFS) and overall survival (OS) were assessed
y the Kaplan-Meier (KM) technique [21]. Risks of
RM and disease relapse were assessed as competing
vents using KM estimates. Univariate analyses of
retransplantation factors inﬂuencing OS and risks of
RM and relapse at 3 years after transplantation were
erformed. Variables that failed to demonstrate cor-
elation with the outcomes (log-rank P  .20) were
xcluded from multivariate analysis. The remaining
otential covariates were incorporated into multivar-
ate Cox proportional hazard models for the 3 end-
oints (death, TRM, and relapse).
ESULTS
atient Characteristics
Patient characteristics are listed in Table 1. Over-
ll, 21 and 30 patients underwent RD and URD trans-
lantation, respectively. In 12 patients (5 RD and 7
RD), MDS resulted from previous therapy for
reast cancer (4), Hodgkin disease (2), colon cancer
1), non-Hodgkin lymphoma (1), amyloidosis (1),
ML (1), acute lymphoblastic leukemia (1), and Be-
çet disease (1). In these patients, previous therapy
as completed a median of 4 years (range, 6 months to
2 years) before diagnosis of MDS.
Disease status was evaluated by FAB classiﬁcation
nd IPSS risk group at diagnosis and immediately
efore transplantation (Table 2). Reasons allogeneic
ransplantation was performed in RA were t-MDS
nd/or poor risk cytogenetics (7), life-threatening cy-
openias (4), or previous RAEB (1).
tem Cells and Engraftment
Twenty of 21 patients undergoing RD transplan-
ation received PBSCs, whereas 1 patient undergoing
D transplantation and all patients undergoing URD
ransplantation received BM cells. For all patients, the
edian (range) total nucleated, CD34, and CD3
ell counts per kilogram were 4.19  108 (.90-33.10),
.42  106 (.39-16.60), and 5.74  107 (.77-100.7),
espectively. For patients undergoing RD transplan-
ation, the median (range) total nucleated, CD34,
nd CD3 cell counts per kilogram were 10.70  108
(
(
U
a
w
4
p
s
m
o
r
p
r
p
w
n
w
c
R
o
F
r
o
G
w
2
o
f
M
b
g
1
n
e
p
G
w
f

R
m
t
w
T
A
P
P
O
C
T
T
D
H
P
C
*
T
A
D
D
T
F
I
*
C. L. Hallemeier et al.7522.92-33.10), 5.46  106 (.39-16.60), and 20.10  107
3.62-100.70), respectively. For patients undergoing
RD transplantation, the median (range) total nucle-
ted, CD34, and CD3 cell counts per kilogram
ere 3.19  108 (.90-4.96), 2.95  106 (.66-7.86), and
.00  107 (.77-8.67), respectively.
able 1. Patient Characteristics
Characteristic Patients, n
ll patients 51
atient age, (y), median (range) 44 (19-70)
atient age distribution (y)
<30 6
30-49 25
50 20
nset of MDS
De novo 39
t-MDS 12
ytogenetics
Normal 13
Complex (>3 clonal abnormalities) or -7/7q- 17
Other clonal abnormalities (<3 total) 14
Not done/unobtainable 7
ime from diagnosis to transplantation
(mo), median (range) 7 (1-95)
herapy before transplantation
None 27
Immunosuppressive therapy only 7
Chemotherapy 17
onor*
RD 21
URD 30
LA matching
A, B, and DR identical 47
Single-antigen mismatch 4
atient-donor CMV serostatus
Negative-negative 15
Donor and/or recipient positive 36
MV indicates cytomegalovirus.
Stem cell source was PBSC for RD transplantation (except for 1
patient who received marrow) and BM for URD transplanta-
tion.
able 2. Disease Status by FAB and IPSS
Classification
Patients, n
At
Diagnosis
At
Transplantation
AB subtype
RA 26 12
RARS* 3 0
RAEB 12 13
RAEB-t 10 9
sAML refractory/untreated 0 9
sAML-CR 0 8
PSS risk
Low 7 3
Intermediate-1 18 10
Intermediate-2 19 15
High 7 6
sAML 0 17RA with ringed sideroblasts.Primary graft failure occurred in 3 of 49 evaluable
atients (6%); secondary graft failure was not ob-
erved. Two patients were not evaluable for engraft-
ent due to early death. Of the 3 patients who deve-
ped graft failure, 1 received RD PBSCs and 2
eceived URD BM. At day 30, 33 of 38 evauable
atients (87%) had 100% donor chimerism in unsepa-
ated marrow nucleated cells. At year 2, 12 of 16 living
atients had chimerism analysis performed, all of
hom had 100% donor cells in unseparated marrow
ucleated cells. In most patients who were alive and
ithout disease at year 3 and beyond, yearly BM
himerism analysis was not performed.
egimen-Related Organ Toxicity
One patient (2%) expired of RROT (NCI grade 5)
n day 22 due to hepatic veno-occlusive disease.
ive patients (10%) developed life-threatening but
eversible organ toxicity (NCI grade 4) due to veno-
cclusive disease (4) or diffuse alveolar hemorrhage (1).
raft-versus-Host Disease
The numbers (percentages) of evaluable patients
ho developed grade 0, 1, 2, 3, and 4 acute GVHD were
1 (46), 13 (28), 3 (7), 7 (15), and 2 (4), respectively. Rates
f grade 2 to 4 acute GVHD were 11% for RD and 37%
or URD transplantation. Using the International Bone
arrow Transplant Registry Severity Index, the num-
ers (percentages) of evaluable patients who developed
rade 0, A, B, C, and D acute GVHD were 21 (46), 2 (4),
5 (33), 5 (11), and 3 (7), respectively. Five patients were
ot evaluable for acute GVHD due to graft failure (3) or
arly death (2). The numbers (percentages) of evaluable
atients who developed no, limited, or extensive chronic
VHD were 6 (19), 2 (6), and 23 (74). Twenty patients
ere not evaluable for chronic GVHD due to graft
ailure (3), death (13), or relapsed disease (4) before day
100.
elapse, TRM, Death, and Survival
Disease relapse occurred in 14 patients (27%) at a
edian (range) of 130 (21-243) days after transplan-
ation (Table 3). Thirteen of these patients expired,
hereas 1 remained alive in a durable second CR after
able 3. Status at Last Follow-up
Status at Last
Follow-Up
All Patients
(n  51)
RD
(n  21)
URD
(n  30)
live, CR 19 (37%) 10 (45%) 9 (30%)
eath, relapsed disease 13 (25%) 5 (24%) 8 (27%)
eath, TRM 19 (37%) 6 (27%) 13 (43%)
Infection 16 6 10
Active GVHD 7 2 5
No GVHD present 9 4 5
GVHD 2 0 2
Organ toxicity 1 0 1
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Intermediate-Dose TBI-Based RIC and Allogeneic BMT for MDS 753ransplantation. This patient had disease relapse at day
160, was reinduced into second CR with chemo-
herapy, and remained in CR with 100% donor chi-
erism at ﬁnal follow-up through day 700.
Overall, 19 patients (37%) expired due to TRM.
ates of TRM through 100 days and 1 year were 25%
nd 35%, respectively. Major causes of TRM included
nfection (16 patients), GVHD (2), and organ toxicity
1). Death from infection was due to bacterial, fungal,
r cytomegalovirus pathogens in 8, 6, and 2 patients,
espectively.
At ﬁnal follow-up, 19 patients (37%) were alive
nd in CR at a median (range) of 3.8 years (1.7-6.4).
astern Cooperative Oncology Group performance
tatus score at ﬁnal follow-up was 0 and 1 in 9 and 10
atients, respectively. Eight patients were off all im-
unosuppression, whereas 11 remained on low-dose
mmunosuppressive therapy. At ﬁnal follow-up, the
umbers of patients with no, limited, and mild exten-
ive chronic GVHD were 13, 5, and 1, respectively.
The KM estimates of OS at 3 years were 88%,
6%, 33%, 11%, and 11% for patients who under-
ent transplantation with sAML in CR, RAEB, RA,
AEB-t, and sAML refractory/untreated, respec-
ively. The KM estimates of RFS at 3 years were 75%,
6%, 33%, 11%, and 11%, respectively. The KM
able 4. Univariate Analysis of the Impact of Pretransplant Characteri
Variables† 3-Year OS (%
AB status at transplantation
RA (n  12) 33
RAEB (n  13) 46
RAEB-t/sAML refractory/untreated (n  18) 11
sAML-CR (n  8) 88
ransplant type
RD (n  21) 48
URD (n  30) 30
atient gender
Female (n  24) 54
Male (n  27) 22
iagnosis to transplantation
<12 mo (n  32) 41
>12 mo (n  19) 32
DS onset
De novo (n  39) 36
t-MDS (n  12) 42
LA-matched (6/6 antigens)
Yes (n  47) 40
No (n  4) 0
D34 dose >2.5  106/kg
Yes (n  38) 42
No (n  13) 23
R indicates relapse risk; NA, not available.
K-M risks treating TRM and RR as competing events.
Other variables considered included patient age (45 versus 4
and/or recipient positive), cytogenetics (complex/-7/7q-; other
variables were signiﬁcant (P  .20) for any of these 3 endpoint
Log rank.stimates of RFS at 3 years were 48% and 27% for hatients undergoing RD and URD transplantations,
espectively.
nivariate and Multivariate Analyses
Univariate analysis was performed to evaluate the
ffect of pretransplantation characteristics on survival,
RM, and relapse risks through 3 years after trans-
lantation (Table 4, Figures 1-3). In this analysis,
ariables signiﬁcantly associated with OS at 3 years
ere FAB status at transplantation and HLA matched
t 6/6 antigens. Patients who underwent transplanta-
ion 12 months after the initial diagnosis of MDS
eveloped a signiﬁcantly increased risk of TRM
hrough 3 years. Several variables were associated with
isk of relapse through 3 years, including FAB status at
ransplantation, gender, interval 12 months from
iagnosis to transplantation, t-MDS, and stem cell
raft containing 2.5  106 CD34 cells/kg.
Multivariate analysis was then performed to deter-
ine the independent effects of the covariates of po-
ential signiﬁcance identiﬁed in the univariate analysis
n the outcomes death, TRM, and relapse (Table 5).
haracteristics independently associated with an in-
reased risk of death were FAB status of RAEB-t or
AML refractory/untreated (relative to sAML-CR;
Outcomes
P‡ 3-Year TRM (%)* P‡ 3-Year RR (%)* P‡
.01 29 .15 53 .04
47 13
71 62
13 14
.19 31 .22 31 .30
51 46
.06 36 .41 16 .01
52 61
.17 28 .004 48 .05
64 13
.51 52 NA 30 .05
0 58
.05 41 .34 35 .14
50 100
.27 43 .86 30 .02
35 65
), cytomegalovirus serology (donor and recipient negative; donor
ydroxychloroquine GVHD prophylaxis (yes; no). None of thesestics on
)*
5 years
), and h
s.azard ratio [HR], 14.5; P  .01), FAB status of RA
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C. L. Hallemeier et al.754relative to sAML-CR; HR, 10.9; P  .03), URD
ransplantation (relative to RD transplantation; HR,
.7; P  .02), transplantation 12 months after diag-
osis (relative to transplantation 12 months after
iagnosis; HR, 2.8; P .02), and male gender (relative
o female; HR, 2.5; P  .04). The only characteristic
ndependently associated with an increased risk of TRM
as transplantation 12 months after diagnosis (HR,
.5; P  .01). Characteristics independently associated
ith an increased risk of disease relapse were male gen-
er (HR, 6.5; P .03) and CD34 dose2.5 106/kg
relative to CD34 dose 2.5  106/kg; HR, 5.1; P 
03). The latter was also statistically signiﬁcant in a mul-
ivariate analysis when treated as a continuous variable
data not shown). Notably, high (versus low) CD34 cell
ose was not associated with increased rates of severe
cute or chronic GVHD in evaluable patients (data not
hown).
ISCUSSION
In large contemporary studies of heterogeneous
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onor type (P  .19). B, FAB status at transplantation (P  .01).ohorts of patients with MDS undergoing allogeneic Dransplantation after conditioning with conventional
egimens, rates of TRM at 3 years ranged from 28%
o 49% and relapse rates at 3 years ranged from 11%
o 25% [6,22,23]. Patient survival varied greatly in
hese studies; overall 3-year RFS was 26% to 59%.
urvival was largely dependent on transplant charac-
eristics including morphologic status of disease at
ransplant (FAB), availability of a matched related do-
or, cytogenetics, t-MDS, and age. In all 51 patients
n the present study, rates of RFS, TRM, and relapse
hrough 3 years were 35%, 37%, and 27%. Therefore,
utcomes observed in this heterogeneous group of
atients with MDS undergoing allogeneic transplan-
ation after conditioning with 550-cGy TBI and cy-
lophosphamide were similar to those observed with
onventional conditioning regimens [6,22,23]. In sub-
et analysis, outcomes of patients with sAML in CR,
AEB, and t-MDS undergoing allogeneic transplan-
ation with this RIC regimen compared favorably to
hose observed with conventional regimens; however,
utcomes of patients with RA, RAEB-t, or refractory/
ntreated sAML conditioned with this regimen were
imilar or worse than those observed after conven-
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Intermediate-Dose TBI-Based RIC and Allogeneic BMT for MDS 755ional conditioning regimens [6,22-24]. The prelimi-
ary results of patients in these subsets should be
nterpreted cautiously because of the small number of
atients in each subset.
In published reports with smaller cohorts of pa-
ients with MDS undergoing allogeneic transplanta-
ion after other RIC or nonmyeloablative regimens,
RM rates ranged from 20% to 44% and relapse rates
anged from 17% to 70% compared with rates of 37%
nd 29%, respectively, in our study [25-30]. In a sub-
et of 20 patients with MDS undergoing RD trans-
lantation at the National Institutes of Health who
eceived RIC with a ﬂudarabine-based (non-TBI) reg-
men, the 3-year probabilities of OS, RFS, TRM, and
elapse were 39%, 37%, 27%, and 58%, respectively
30]. In comparison, in the 21 patients in the present
tudy undergoing RD transplantation, the 3-year risks
f OS, RFS, TRM, and relapse were 48%, 48%, 31%,
nd 31%, respectively. In the subset of 20 patients
ith MDS undergoing URD transplantation after
onmyeloablative conditioning with 200 cGy of TBI
≥ 12 months (n=19)
< 12 months (n=32)
A
B
C
um
ul
at
iv
e 
R
is
k 
C
um
ul
at
iv
e 
R
is
k 
Time (years)
Time (years) 
sAML-CR (n=8)
RAEB (n=13)
RAEB-t/sAML-active (n=18)
RA (n=12)
igure 3. KM TRM risk, with tick marks representing living
atients and relapse events. A, Interval from diagnosis to transplan-
ation (P  .004). B, FAB status at transplantation (P  .15).nd ﬂudarabine, 20% of patients were alive at a max- smum follow-up of 1.6 years, whereas 45% and 35%
f patients expired due to relapsed disease and TRM,
espectively [31]. In the present study, 25 patients
nderwent URD transplantation and 30% remained
live at a minimum follow-up of 1.9 years, whereas
7% and 43% expired due to relapsed disease and
RM, respectively. However, it is difﬁcult to make
irect comparisons between outcomes observed with
llogeneic transplantation after this novel RIC regi-
en and those observed with other RIC and nonmy-
loablative regimens due to important differences in
atient populations and follow-up duration. In con-
rast to our study, with most reports of other RIC and
onmyeloablative regimens, patients were recruited
ased on ineligibility for standard conditioning regi-
ens due to advanced age or underlying comorbidi-
ies. However, in studies of other RIC and nonmy-
loablative regimens, the median follow-up in living
atients was shorter (8-30 months), leaving many pa-
ients still at risk for TRM and relapse events [25-31].
minority of patients had follow-up of3 years, with
uration of RFS often associated with cure. In con-
rast, the median follow-up in the present study was
.8 years and TRM and relapse events reached a
lateau at approximately 1.6 years. Notably, all sur-
iving patients had1.7 years of follow-up, with most
11) living 3 years. These results demonstrate the
urative potential of allogeneic transplantation in pa-
ients with MDS conditioned with a RIC regimen of
50 cGy of TBI and cyclophosphamide.
In patients with MDS, the proper timing of allo-
eneic transplantation that optimizes survival out-
omes remains unknown. A recent retrospective study
ound that delayed transplantation in patients with
ower-risk MDS (low or intermediate IPSS, 1) under-
oing matched-sibling allogeneic transplantation after
onventional regimens resulted in optimized survival
ates and discounted life expectancy [32]. The ideal
iming of allogeneic transplantation with nonmyeloa-
lative and RIC regimens in patients with MDS has
ot been examined. In the present study, delayed
ransplantation (12 months after diagnosis) was in-
ependently associated with signiﬁcantly greater risks
f TRM and overall death. A similar observation was
ade in patients with MDS undergoing conventional
onditioning and allogeneic transplantation, most of
hom also received URD marrow [23]. The explana-
ion for this observation is unclear, but may relate to
cquired comorbidities. Although the patient cohort
n the present study was small, preliminary evidence
uggests an advantage to early transplantation for pa-
ients with MDS undergoing allogeneic transplanta-
ion with this RIC regimen.
In the present study, low CD34 cell dose was
ssociated with a signiﬁcantly higher risk of disease
elapse after transplantation. The reason for this ob-
ervation is unclear, although a small (versus large)
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C. L. Hallemeier et al.756raft cell dose has been associated with delayed en-
raftment and/or poorer OS in large studies of pa-
ients with hematologic malignancies undergoing al-
ogeneic transplantation after conventional regimens
33-35]. In patients undergoing allogeneic transplan-
ation after RIC regimens of 200-cGy TBI and ﬂu-
arabine or ﬂudarabine and melphalan, stem cell
rafts with low CD3 and CD34 cell counts, respec-
ively, were associated with poorer survival [27,31].
ne potential hypothesis for these observations is that
atients who receive smaller grafts may develop de-
ayed donor immune reconstitution and, hence, de-
ayed graft-versus-malignancy effects. Although other
tudies have observed that graft-versus-malignancy
orrelated with clinical GVHD, we did not observe
igniﬁcantly different rates of clinical acute or chronic
VHD between patients who received low (2.5 
06/kg) and those who received high CD34 cell
oses. Therefore, this observation is intriguing but
hould be interpreted with caution because patient
umbers in the present study were small and graft
omposition (BM or PBSC) and immunosuppressive
egimens were heterogeneous.
In this study, 550-cGy TBI and cyclophosphamide
s conditioning for patients with MDS and sAML
esulted in long-term survival in a signiﬁcant propor-
ion of patients (37%). In sAML-CR, RAEB, and
-MDS patient subsets, survival compared favorably to
hat reported in patients undergoing allogeneic trans-
able 5. Multivariate Analysis of the Impact of Pretransplant Characte
Covariates
Death*
HR (95% CI)
AB status at transplantation
sAML-CR 1.0
RAEB 5.6 (.7-46)
RA 10.9 (1.3-99)
RAEB-t/sAML refractory/untreated 14.5 (1.8-114)
ransplant type
RD 1.0
URD 2.7 (1.2-6.5)
atient sex
Female 1.0
Male 2.5 (1.1-5.7)
iagnosis to transplantation
<12 mo 1.0
>12 mo 2.8 (1.2-6.7)
DS onset
De novo NA
t-MDS
LA-matched (6/6 antigens)
Yes 1.00
No 1.1 (.3-3.9)
D34 dose >2.5  106/kg
Yes NA
No
R indicates hazard ratio; CI, conﬁdence interval; NA, not availab
Analyzed with the Cox proportional hazards model.lantation after conventional regimens. In a multivar-ate analysis, several pretransplantation variables were
dentiﬁed that inﬂuenced survival, TRM, and relapse
utcomes. The data from this report support that
50-cGy TBI and cyclophosphamide is an effective
IC regimen for RD and URD transplantation in
atients with MDS, but is not convincingly superior to
ther RIC regimens or conventional conditioning
egimens.
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